Recent News

Athenex Provides Second Quarter 2022 Financial Results and Business Update

Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology

Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.

Athenex to Participate in Truist Securities Cell Therapy Symposium

Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree

Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy

Athenex Announces Clinical Collaboration with Merck to Evaluate Oraxol plus KEYTRUDA® (pembrolizumab) in Patients with Non-Small Cell Lung Cancer (NSCLC)

Athenex Provides First Quarter 2022 Financial Results and Business Update

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.

Learn more

Investors

View press releases, events and presentations, and other investment information

Learn more

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.

Learn more